Scilex Holding Company (SCLX)

USD 0.46

(-8.94%)

Market Cap (In USD)

88.1 Million

Revenue (In USD)

46.74 Million

Net Income (In USD)

-114.33 Million

Avg. Volume

1.03 Million

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.4411-2.63
PE
-
EPS
-
Beta Value
1.15
ISIN
US80880W1062
CUSIP
80880W106
CIK
1820190
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Mr. Jaisim Shah
Employee Count
-
Website
https://www.scilexholding.com
Ipo Date
2021-03-05
Details
Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid management products for the treatment of acute and chronic pain. Its commercial product is ZTlido 1.8%, a prescription lidocaine topical product for the relief of neuropathic pain related with post-herpetic neuralgia, which is a form of post-shingles nerve pain. It also offers SP-102, a viscous gel formulation of corticosteroid for epidural injections that is in a Phase III clinical trial to treat lumbosacral radicular pain; SP-103, which is in Phase II clinical trail for the treatment of low back pain; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation that has completed Phase I clinical trial for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California. Scilex Holding Company is a subsidiary of Sorrento Therapeutics, Inc.

More Stocks